MedTrace Logo

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma

NCT00245141 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving vincristine, dactinomycin, and cyclophosphamide together with or without radiation therapy works in treating patients with embryonal rhabdomyosarcoma.

Conditions

  • Sarcoma

Interventions

BIOLOGICAL

dactinomycin

DRUG

cyclophosphamide

DRUG

vincristine sulfate

RADIATION

radiation therapy

Sponsors & Collaborators

  • Japan Rhabdomyosarcoma Study Group

    lead OTHER

Principal Investigators

  • Hajime Hosoi · Kyoto Prefectural University of Medicine

  • Masa-aki Kumagai, MD · National Center for Child Health and Development

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2011-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245141 on ClinicalTrials.gov